ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

NUVB vs STOK // EV/EBITDA & P/E VALUATION

Nuvation Bio Inc. (Class A) (NYSE) VS. Stoke Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: NUVB 0 — STOK 8
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NUVB VS. STOK) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC NUVB STOK SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -6.10% -28.90 STOK /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -10.35% 2.64% -12.99 STOK /fcf-yield <GO>
Operating Margin -60.00% -11.20% -48.80 STOK /operating-margins <GO>
Net Profit Margin -60.00% -3.70% -56.30 STOK /net-margins <GO>
Revenue Growth (YoY) 180.00% 180.00% 0.00 TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.76 14.79 -14.03 STOK /balance-sheet <GO>
Piotroski F-Score Quality 4/9 6/9 -2.00 STOK /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 42.2 52.3 -10.07 STOK /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.67B $1.70B -$25.4M STOK /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR NUVB REV STOK REV NUVB GROSS % STOK GROSS % NUVB FCF STOK FCF
FY 2025 $62.9M $184.4M — — -$173.4M $44.9M
FY 2024 $7.9M $36.6M 10.1% — -$130.4M -$87.1M
FY 2023 $0 $8.8M — — -$68.0M -$81.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NUVB // BETA —
STOK // BETA —